233 related articles for article (PubMed ID: 26576103)
1. Research progress and prospects of markers for liver cancer stem cells.
Zhu CP; Wang AQ; Zhang HH; Wan XS; Yang XB; Chen SG; Zhao HT
World J Gastroenterol; 2015 Nov; 21(42):12190-6. PubMed ID: 26576103
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of signaling pathways and putative biomarkers in liver cancer stem cells (Review).
Song K; Wu J; Jiang C
Oncol Rep; 2013 Jan; 29(1):3-12. PubMed ID: 23076400
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells.
Wilson GS; Hu Z; Duan W; Tian A; Wang XM; McLeod D; Lam V; George J; Qiao L
Stem Cells Dev; 2013 Oct; 22(19):2655-64. PubMed ID: 23638793
[TBL] [Abstract][Full Text] [Related]
4. The power and the promise of liver cancer stem cell markers.
Liu LL; Fu D; Ma Y; Shen XZ
Stem Cells Dev; 2011 Dec; 20(12):2023-30. PubMed ID: 21651381
[TBL] [Abstract][Full Text] [Related]
5. Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies.
Liu YC; Yeh CT; Lin KH
Cells; 2020 May; 9(6):. PubMed ID: 32466488
[TBL] [Abstract][Full Text] [Related]
6. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
Wang R; Sun Q; Wang P; Liu M; Xiong S; Luo J; Huang H; Du Q; Geller DA; Cheng B
Oncotarget; 2016 Feb; 7(5):5754-68. PubMed ID: 26735577
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
8. Liver cancer stem cell markers: Progression and therapeutic implications.
Sun JH; Luo Q; Liu LL; Song GB
World J Gastroenterol; 2016 Apr; 22(13):3547-57. PubMed ID: 27053846
[TBL] [Abstract][Full Text] [Related]
9. Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133.
Hur W; Ryu JY; Kim HU; Hong SW; Lee EB; Lee SY; Yoon SK
Sci Rep; 2017 Apr; 7():45557. PubMed ID: 28367990
[TBL] [Abstract][Full Text] [Related]
10. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
Nio K; Yamashita T; Okada H; Kondo M; Hayashi T; Hara Y; Nomura Y; Zeng SS; Yoshida M; Hayashi T; Sunagozaka H; Oishi N; Honda M; Kaneko S
J Hepatol; 2015 Nov; 63(5):1164-72. PubMed ID: 26095183
[TBL] [Abstract][Full Text] [Related]
11. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
12. Isolation, identification, and characterization of cancer stem cells: A review.
Abbaszadegan MR; Bagheri V; Razavi MS; Momtazi AA; Sahebkar A; Gholamin M
J Cell Physiol; 2017 Aug; 232(8):2008-2018. PubMed ID: 28019667
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of liver cancer stem cells and clinical correlations.
Cheng Z; Li X; Ding J
Cancer Lett; 2016 Sep; 379(2):230-8. PubMed ID: 26272183
[TBL] [Abstract][Full Text] [Related]
15. Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative-nitrosative stress signals.
Zhang J; Pei Y; Yang W; Yang W; Chen B; Zhao X; Long S
Mol Carcinog; 2019 Mar; 58(3):334-343. PubMed ID: 30365183
[TBL] [Abstract][Full Text] [Related]
16. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment.
Song YJ; Zhang SS; Guo XL; Sun K; Han ZP; Li R; Zhao QD; Deng WJ; Xie XQ; Zhang JW; Wu MC; Wei LX
Cancer Lett; 2013 Oct; 339(1):70-81. PubMed ID: 23879969
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.
Hirata H; Sugimachi K; Takahashi Y; Ueda M; Sakimura S; Uchi R; Kurashige J; Takano Y; Nanbara S; Komatsu H; Saito T; Shinden Y; Iguchi T; Eguchi H; Atsumi K; Sakamoto K; Doi T; Hirakawa M; Honda H; Mimori K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1402-9. PubMed ID: 25404478
[TBL] [Abstract][Full Text] [Related]
18. [Novel therapeutic strategies for treatment of hepatocellular carcinoma: targeting intervention on liver cancer stem cells].
Li X; Luo Q; Song G
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Aug; 30(4):894-8. PubMed ID: 24059077
[TBL] [Abstract][Full Text] [Related]
19. 8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.
Ren KQ; Cao XZ; Liu ZH; Guo H; Quan MF; Liu F; Jiang L; Xiang HL; Deng XY; Cao JG
Int J Oncol; 2013 Nov; 43(5):1719-29. PubMed ID: 23970349
[TBL] [Abstract][Full Text] [Related]
20. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
